Seeking Alpha

Michael Sweeney's  Instablog

Michael Sweeney
Send Message
Michael Sweeney is the Managing Partner of Film Annex Capital Partners, LLC, the venture division of Film Annex, and he is the Executive Producer of Hedgers, Bankers, and Thinkers, a WebTV series on Film Annex. FilmAnnex.com is ranked as one of the Top 100 web sites in America with over 25+... More
My company:
Hedgers, Bankers and Thinkers @ Film Annex
My blog:
Film Annex Capital Partners Blog
  • "I think devices play a huge role in patient preference” - Sanofi CEO 0 comments
    Sep 22, 2011 10:51 AM | about stocks: SNY

    "I think devices play a huge role in patient preference, as we’ve seen in other sectors.” Chris Viehbacher, CEO of Sanofi-aventis, September 14, 2011

    Sanofi-aventis is a diversified global healthcare leader that discovers, develops, produces and markets innovative therapies that enhance people’s lives. The Company's research and development efforts are focused on health care challenges in cardiology, oncology and internal medicine, as well as metabolic diseases, central nervous system disorders, ophthalmology and vaccines.

    Since the end of 2008, Sanofi has led an impressive transformation by executing a new strategy focused on three pillars:

    1. Increase innovation in R&D,

    2. Pursue external growth opportunities, and

    3. Adapt structure for future challenges and opportunities.

    Over this period, Sanofi has centered its activities around six growth platforms including Emerging Markets, Human Vaccines, Diabetes solutions, Consumer Health Care, Innovative Products and Animal Health.

    At Sanofi's recent IR Thematic Seminar on September 6, 2011, Chris Viehbacher, CEO of Sanofi-aventis spoke in his presentation about:

    "Value creating opportunities through product differentiation" and

    "Sustain Leadership and value creation through differentiation"

    This week at the Morgan Stanley Health Care Conference, Sanofi's CEO Chris Viehbacher had the following exchange during a call:

    Morgan Stanley: So I can then follow up on a couple of these point. Probably I think I know [indiscernible] anything additionally you’d like to comment to, any additional comments on the new formulation of Lantus. And secondly, I always speak to doc’s in Cairo’s, they are very excited about the idea of the GLP-1 insulin combine. Could you remind us where we are with the Sanofi Lantus mix in a combine thing?

    Christopher A. Viehbacher: I think we just completed Phase I on the new formulation, so we thought we needed to kind of put this on investors radar screens, but clearly there’s a lot of competitive sensitivity around this...

    I think the GLP-1 one is an extraordinary combination because couple with the weight loss and way these two molecules interact is a unique opportunity for Sanofi, I think being able to put this in the single device, we expect to go into Phase III at the beginning of 2013. We got to delay largely because the FDA had required us to do the Phase III studies in the actual marketed device. So we need to finalize that device to be able to do it. It’s not that easy to do these combinations just so that people understand. I mean, you got to have a device that allows you to still be able to titrate the dose of your insulin as well as providing a fixed dose of the GLP-1, you talking about liquid suspensions here and so you can’t just mix them, you cant just put these two into -- so you’re going to have to develop devices that allow that kind of level to sophistication. And I think that’s where we are and I think devices play a huge role in patient preference as we’ve seen in other sectors. So, GLP-1 or submitting in the early part of 2012, so we’ll have that at a -- we have that Lantus and GLP-1 being sold separately. And then Phase III goes into -- and Phase III starts in the first quarter of 2013.

    Chris Viehbacher, CEO of Sanofi-aventis is viewed in the pharma industry as a "thought leader" in the space as seen below in this recent interview and clearly devices are a focus for Sanofi in creating a value-add to their traditional products:

    Stocks: SNY
Back To Michael Sweeney's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.